SENATE MEDICARE BILL WOULD SIMPLIFY DME UPGRADE PURCHASES; FINANCE COMMITTEE APPROVES PART B COMPETITIVE BIDDING, 37.5% OXYGEN PAYMENT CUT
This article was originally published in The Gray Sheet
Purchasing of upgraded or enhanced durable medical equipment would be simplified under the Medicare bill unanimously approved by the Senate Finance Committee June 18. The provision would make it easier for beneficiaries to buy higher-end DME by incurring only the difference in cost between the upgrade and the standard model as an out-of-pocket expense, with DME suppliers being reimbursed for the cost of the standard item.
You may also be interested in...
A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.
2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.